Food Safety Finds a Place Among ‘Kitchen-Table’ Political Issues
The run-up to the midterm elections is turning into a food fight — literally. The…
Food Safety Finds a Place Among ‘Kitchen-Table’ Political Issues
The run-up to the midterm elections is turning into a food fight — literally. The summer was marred by a massive foodborne outbreak that sickened scores of people and the recall of tens of thousands of pounds of imported meat, turning the safety of the U.S. food supply into a topic of national conversation and…
Republicans and Democrats Find a Unifying Target: Pharmacy Benefit Managers
Amye Joseph says America’s political polarization has made it an “interesting time” in her Tennessee household. She and her husband, Charlie, have been married 35 years. She’s a Republican. He’s a Democrat. But their shared disenchantment with profit-driven healthcare has provided a unifying target: pharmacy benefit managers, known as PBMs. The Josephs’ frustration is focused…
THCB Gang Special — The Odyssey of Women’s Health: Journeying into the Midterms
Audrey Mann Cronin takes over THCB today and has a THCB Gang special called “The Odyssey of Women’s Health: Journeying into the Midterms – Obstacles, Opportunities and What We Can Expect” The panel is Liz Powell, an attorney and Founder of both G2G Consulting and Women’s Health Advocates, and former Capitol Hill staffer; Dr. Elizabeth…
Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder
Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year. The post Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder…
When AI Gets Medicine Wrong, Who’s Liable?
As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care? The post When AI Gets Medicine Wrong, Who’s Liable? appeared first on MedCity News.
Fifty Years of Pediatric Rheumatology, but Children Still Can’t Access the Treatments They Need
As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change. The post Fifty Years of Pediatric Rheumatology, but Children Still Can’t Access the Treatments They Need appeared…
MedTech Commercialization Gap: Moving Beyond Technical Viability
What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem. The post MedTech Commercialization Gap: Moving Beyond Technical Viability appeared first on MedCity News.
Journalists Discuss What RFK Jr. Recently Told the Anti-Vaccine Group He Founded
KFF Health News contributor Erin Rode discussed California prison heat protections on KVPR’s Central Valley Daily on Sept. 24. Click here to hear Rode on Central Valley Daily. Read Rode’s “California Eyes Prison Heat Protections That Fall Short of Workplace Standards.” KFF Health News chief Washington correspondent Julie Rovner discussed the removal of more than…
Report: High Drug Costs Are Creating Hidden Burden for Physicians
When drug prices are too high for patients, physicians take on additional workload to find solutions. A newly released 2026 Physician Drug Cost Survey by RazorMetrics examined how prescription cost pressures affect physicians’ practices. The post Report: High Drug Costs Are Creating Hidden Burden for Physicians appeared first on MedCity News.
Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut
ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary angioedema, and the RNA therapies pipeline also spans immunological disorders, cardiovascular diseases and obesity, and neurodegeneration. The post Gene Silencing-Biotech ADARx Makes Some Noise With…
